ORPHAN PHARMA INTERNATIONAL

a subsidiary of EUSA PHARMA LTD
  • March 1st, 2007, OPi became a division of Eusa Pharma.

    Orphan Pharma International (OPi), Pharmaceuticals for Rare Diseases is a biopharmaceutical company involved in the development and marketing of innovative drugs to treat rare and severe diseases. OPi explores new therapeutic approaches and also works as a ?re-discovery engine?, turning unnoticed drug opportunities into products that are made available to the hospitals physicians and pharmacists, to help them meeting the medical needs of the patients and their families, and improving their quality of life.

    Dedicated to help people with rare and severe diseases, the company is focused on the areas of haematological cancers, while being also active in neurology and toxicology.
  • Snapshot

    Business TypeSectorSubsectorFounded
    Standard / RnDBiotechnologyImmunity
    Biotechnology
    1999
Registered Office
,
France
Tel.